HCV Clinical Trial
Official title:
National Prisons Hepatitis Education Project: Research Evaluation
The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison. The HepPEd Program aims to improve the public health literacy of the prison sector regarding hepatitis C in prisons. The HepPEd: Research Evaluation aims to evaluate the impact of the HepPEd Program on HCV testing and treatment uptake amongst people incarcerated in Australian prisons, as well as changes in knowledge, attitudes, and capabilities of healthcare providers, correctional officers, and people in prison. The study is a controlled before and after study being conducted in 3-6 correctional centres in Australia.
The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison. The broad goal of HepPEd: Research Evaluation is to measure the impact of a prison-specific hepatitis C (HCV) education program (the HepPEd Program) on enhancing HCV testing and treatment rates in Australian prisons. The HepPEd Program aims to improve HCV testing and treatment rates by enhancing the public health literacy of the prison sector regarding HCV in the prisons (that is the knowledge, attitudes and behaviours), and specifically targets the three key audience groups from the prison setting: healthcare providers, correctional officers, and people in prison. The study will be conducted as a prison-level, controlled before-and-after trial with a primary objective of evaluating the impact of the HepPEd Program on HCV treatment uptake amongst people incarcerated in Australian prisons. Three to six Australian correctional centres will be selected to participate in the 9-month study. Each correctional centre will have a 3-month period of pre-intervention surveillance, involving monthly observation of HCV treatment uptake under existing operations. This will be followed by a three-month period of education delivery of the HepPEd Program (the 'education intervention'). The monthly surveillance data collection will continue during the intervention period. Finally, each correctional centre will have another 3-month period of post-intervention surveillance, again involving monthly surveillance of HCV treatment rates. Surveys will be conducted with members from each target audience group before and after the education intervention and dried blood spot testing will be conducted with members from the people in prison group to assess baseline HCV prevalence before the education intervention. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
| Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
| Recruiting |
NCT05794646 -
Community Intervention to Eliminate HCV Among People Who Use Drugs.
|
N/A | |
| Completed |
NCT04971330 -
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
|
||
| Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
| Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A | |
| Recruiting |
NCT03981445 -
Integrated HIV Prevention and HCV Care for PWID
|
N/A | |
| Completed |
NCT02452814 -
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
|
N/A | |
| Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
| Not yet recruiting |
NCT06316739 -
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
|
N/A | |
| Completed |
NCT02116543 -
TD-6450 MAD Study in HCV Infected Subjects
|
Phase 1 | |
| Recruiting |
NCT05454579 -
The South-East Asian Transgender Health Cohort
|
||
| Active, not recruiting |
NCT03221309 -
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
|
||
| Completed |
NCT03801707 -
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03820102 -
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
|
||
| Completed |
NCT01074008 -
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
|
Phase 2 | |
| Completed |
NCT05616598 -
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05854511 -
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
|
Phase 3 | |
| Completed |
NCT03069001 -
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV
|
Phase 4 | |
| Completed |
NCT01842451 -
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
|
Phase 2 |